Tolerability of Intravenously Administered Immune Globulin in the Home Setting

Patients with primary immune deficiencies and many neurological disorders are frequently treated with immune globulin, administered intravenously or subcutaneously. The aim of this large-scale, retrospective, longitudinal cohort analysis was to describe tolerability of an intravenously administered immune globulin (IVIG) product in patients in the home setting.

Using data from the Accredo Therapeutics electronic medical records, patients were followed for approximately one year and evaluated on three components to estimate tolerability.

Researchers concluded that intravenous administration of immune globulin is an important alternative infusion option for patients.

Tankersley MA, D’Albini, LD, Steinberg, SC; Accredo Therapeutics, a division of Accredo Health Group, Inc.

Presented at the 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 2009. Click here to view the clinical summary.